人 pTau181 抗体对
01AB00051
Plasma phosphorylated tau 181 (p-tau181) has emerged as a promising biomarker for Alzheimer's disease (AD) and related conditions. Studies show that elevated plasma p-tau181 levels are associated with increased amyloid-beta (Aβ) deposits across various brain regions in cognitively healthy adults. Furthermore, p-tau181 levels correlate with Aβ-positivity on positron emission tomography (PET), and they predict the conversion to dementia stage depending on renal function. However, p-tau181 does not appear to be directly linked to tau-PET burden.Additionally, plasma p-tau181 levels have been associated with cognitive decline in various populations, such as those with AD, mild cognitive impairment (MCI), and other neurodegenerative diseases. Moreover, p-tau181 levels have been identified as a noninvasive diagnostic and prognostic tool in clinical practice and trials.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- MAPT
- 蛋白别名
- Microtubule-associated protein tau; pTau181
- UniProt
- P10636-8
- 物种
- Human
产品详情
- 靶点名称
- pTau181
- 蛋白名称
- Microtubule-associated protein tau
- 靶点基因名
- MAPT
- UniProt
- P10636-8
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
Plasma phosphorylated tau 181 (p-tau181) has emerged as a promising biomarker for Alzheimer's disease (AD) and related conditions. Studies show that elevated plasma p-tau181 levels are associated with increased amyloid-beta (Aβ) deposits across various brain regions in cognitively healthy adults. Furthermore, p-tau181 levels correlate with Aβ-positivity on positron emission tomography (PET), and they predict the conversion to dementia stage depending on renal function. However, p-tau181 does not appear to be directly linked to tau-PET burden.Additionally, plasma p-tau181 levels have been associated with cognitive decline in various populations, such as those with AD, mild cognitive impairment (MCI), and other neurodegenerative diseases. Moreover, p-tau181 levels have been identified as a noninvasive diagnostic and prognostic tool in clinical practice and trials.